secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001654954-24-009066
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies ENDRA Life Sciences of delisting due to bid price; company to appeal
--------------------------------------------------------------------------------

- Stock closed below $0.10 for 10 consecutive trading days ended July 12, triggering delisting under Nasdaq Rule 5810(c)(3)(A)(iii).
- Company requested hearing on July 16; hearing request automatically stays delisting pending panel decision.
- At August 6 annual meeting, company will seek stockholder approval for reverse stock split at ratio between 1:20 and 1:50.
- No assurance that Nasdaq panel will grant compliance period or that company will ultimately regain listing compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424009066/0001654954-24-009066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424009066/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-009066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer